69 results on '"Kangaharan, Nadarajah"'
Search Results
52. TEXT messages to improve MEDication adherence and Secondary prevention (TEXTMEDS) after acute coronary syndrome: a randomised clinical trial protocol
- Author
-
Chow, Clara K, primary, Thiagalingam, Aravinda, additional, Santo, Karla, additional, Kok, Cindy, additional, Thakkar, Jay, additional, Stepien, Sandrine, additional, Billot, Laurent, additional, Jan, Stephen, additional, Joshi, Rohina, additional, Hillis, Graham S, additional, Brieger, David, additional, Chew, Derek P, additional, Rådholm, Karin, additional, Atherton, John J, additional, Bhindi, Ravinay, additional, Collins, Nicholas, additional, Coverdale, Steven, additional, Hamilton-Craig, Christian, additional, Kangaharan, Nadarajah, additional, Maiorana, Andrew, additional, McGrady, Michelle, additional, Shetty, Pratap, additional, Thompson, Peter, additional, Rogers, Anthony, additional, and Redfern, Julie, additional
- Published
- 2018
- Full Text
- View/download PDF
53. Cardiac care for Indigenous Australians: practical considerations from a clinical perspective
- Author
-
Walsh, Warren F, primary and Kangaharan, Nadarajah, additional
- Published
- 2017
- Full Text
- View/download PDF
54. Heart failure with preserved ejection fraction: A growing global epidemic.
- Author
-
Pyi Naing, Forrester, Douglas, Kangaharan, Nadarajah, Muthumala, Aruna, Su Mon Myint, and Playford, David
- Subjects
HEART failure ,LEFT ventricular hypertrophy ,CHRONIC kidney failure ,HYPERTENSION ,ECHOCARDIOGRAPHY - Abstract
Background Heart failure with preserved ejection fraction (HFpEF) is an emerging global health problem of which there is limited awareness. HFpEF has a prognosis similar to that of heart failure with reduced ejection fraction (HFrEF) and accounts for approximately half of all patients with heart failure. Objective The aim of this article is to review HFpEF and its consequences and management, including examples of patients with HFpEF. Discussion Patients with HFpEF may present with dyspnoea, fluid retention, lethargy and dizziness, making it difficult to differentiate clinically from HFrEF. The risk factors include increasing age, obesity, hypertension, diabetes, chronic kidney disease and obstructive sleep apnoea. The diagnosis requires good clinical acumen combined with echocardiography and elevated plasma B-type natriuretic peptide concentration Management of HFpEF, especially in later stages, is difficult as there is no evidence-based therapy to date. Prevention is the best strategy. Early recognition and diagnosis are also very important to tackle this global epidemic. [ABSTRACT FROM AUTHOR]
- Published
- 2019
55. Aboriginal and Torres Strait Islander Cardiovascular Health 2016: Is the Gap Closing?
- Author
-
Walsh, Warren, primary and Kangaharan, Nadarajah, additional
- Published
- 2016
- Full Text
- View/download PDF
56. An unusual case of amaurosis fugax due to papillary fibroelastoma of cor triatriatum
- Author
-
Kangaharan Nadarajah, Majo X. Joseph, Fei Chong, Jay Thakkar, and Jayme Bennetts
- Subjects
medicine.medical_specialty ,Amaurosis Fugax ,Heart Neoplasms ,Internal medicine ,Cor Triatriatum ,Heart rate ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical history ,Heart Atria ,medicine.diagnostic_test ,business.industry ,Cardiorespiratory fitness ,General Medicine ,Amaurosis fugax ,Middle Aged ,medicine.disease ,Blood pressure ,Papillary fibroelastoma ,Echocardiography ,Cor triatriatum ,Cardiology ,Female ,Radiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,Chest radiograph ,business - Abstract
A 58-year-old woman with no significant medical history presented to us with a transient left-sided visual loss. Apart from previous smoking, she had no risk factors for cerebrovascular event. On examination, she had a regular heart rate of 64/min and a blood pressure of 120/90 mmHg. Neurological and cardiorespiratory examinations were unremarkable. Chest radiograph, electrocardiogram, laboratory data, and computed tomography head were unrevealing. A transthoracic …
- Published
- 2011
57. PW370 Development of Nurse led Heart Failure Program for Indigenous and Non Indigenous clients in the Top End of the Northern Territory, Australia
- Author
-
Haste, Mark, primary, Ilton, Marcus, additional, Auckram, Hugh, additional, Iyngkaran, Pupalan, additional, and Kangaharan, Nadarajah, additional
- Published
- 2014
- Full Text
- View/download PDF
58. PT431 Role of care co-ordination and case conferencing in managing pre and post operative challenges in the NT remote indigenous patients with severe rheumatic heart disease
- Author
-
Kangaharan, Nadarajah, primary, Ilton, Marcus, additional, Iyngkaran, Pupalan, additional, and Farquharson, Colin, additional
- Published
- 2014
- Full Text
- View/download PDF
59. Role of Care Co-ordination and Case Conferencing in Managing Pre and Post Operative Challenges in the NT Remote Indigenous Patients with Severe Rheumatic Heart Disease
- Author
-
Kangaharan, Nadarajah, primary, Ilton, Marcus, additional, Farquharson, Colin, additional, Iyngkaran, Pupalan, additional, and Wicks, Mary, additional
- Published
- 2014
- Full Text
- View/download PDF
60. A Retrospective Analysis of Management Outcomes between the Indigenous and Non Indigenous Patients Admitted with Acute Coronary Syndromes (ACS) at Royal Darwin Hospital (RDH) between 2010 and 2011
- Author
-
Prakash, Roshan, primary, Ilton, Marcus, additional, Farquharson, Colin, additional, and Kangaharan, Nadarajah, additional
- Published
- 2014
- Full Text
- View/download PDF
61. Tu1693 Indigenous Australians (IA) Have a Distinctive Gut Microbial Profile Compared to Patients With Inflammatory Bowel Disease (IBD) and Non Indigenous Controls
- Author
-
Iyngkaran, Guru, primary, Kang, Seungha, additional, McSweeney, Chris, additional, Sivanesan, Suresh, additional, Kangaharan, Nadarajah, additional, Morrison, Mark, additional, and Macrae, Finlay A., additional
- Published
- 2013
- Full Text
- View/download PDF
62. Abstract 16486: Exercise Capacity and All-Cause Mortality in Remote Indigenous and Non-Indigenous Populations
- Author
-
Chang, Donald D, Kangaharan, Nadarajah, Forde, Jason, Goh, Daniel, Elangovan, Harendran, Manek, Nimisha, Arauz, Claudia, Brady, Stephen, Sanders, Prashanthan, and Wong, Christopher X
- Abstract
Background:Exercise capacity is a powerful predictor of all-cause mortality. However, it is unclear whether this association is similar in remote Indigenous populations. Central Australia is the most populous Indigenous region faced with a disproportionate burden of morbidity and mortality. Given their geographical isolation from tertiary centers, exercise testing could provide useful risk-stratification locally.Purpose:To characterize the association of exercise capacity with all-cause mortality in Indigenous and non-Indigenous individuals residing in Central Australia.Methods:Demographic, clinical and medication data were prospectively collected from patients undergoing exercise stress tests between 2007-2017. Patients were followed up for all-cause mortality.Results:A total of 3,414 patients (34% Indigenous, mean age 49?13) were included. At 4.8?2.9 years of follow-up, 86 (2.5%) deaths had occurred. Each 1-MET increase in exercise capacity conferred a 12% lower risk for mortality among Indigenous individuals (HR 0.88, 95% CI 0.80-0.97) and 16% lower risk for mortality among non-Indigenous individuals (HR 0.84, 95% CI 0.75-0.94) after adjusting for age, comorbidities, and medications. Mortality risk reduction for each 1-MET increase in exercise capacity was similar (p=0.46) for both Indigenous and non-Indigenous individuals.Conclusions:Exercise capacity is a significant predictor of all-cause mortality in remote Indigenous and non-Indigenous individuals residing in remote Australia, with similar impact according to ethnicity. These findings have important clinical implications towards exercise capacity for risk-stratification and the preventative importance of physical activity.
- Published
- 2019
- Full Text
- View/download PDF
63. Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia
- Author
-
<p>Raine Clinical Research Fellowship Western Australian Health Translation Network (WAHTN) Early Career Fellowship Australian Government's Medical Research Future Fund</p>, Watts, Gerald F., Sullivan, David R., Hare, David L., Kostner, Karam M., Horton, Ari E., Bell, Damon A., Brett, Tom, Trent, Ronald J., Poplawski, Nicola K., Martin, Andrew C., Srinivasan, Shubha, Justo, Robert N., Chow, Clara K., Pang, Jing, Ademi, Zanfina, Ardill, Justin J., Barnett, Wendy, Bates, Timothy R., Beilin, Lawrence J., Bishop, Warrick, Black, J. Andrew, Brett, Peter, Brown, Alex, Burnett, John R., Bursill, Christina A., Colley, Alison, Clifton, Peter M., Ekinci, Elif I., Elias, Luke, Figtree, Gemma A., Forge, Brett H., Garton-Smith, Jacquie, Graham, Dorothy F., Hamilton-Craig, Ian, Hamilton-Craig, Christian R., Heal, Clare, Hespe, Charlotte M., Hooper, Amanda J., Howes, Laurence G., Ingles, Jodie, Irvin, John, Janus, Edward D., Kangaharan, Nadarajah, Keech, Anthony C., Kirke, Andrew B., Kritharides, Leonard, Kyle, Campbell V., Lacaze, Paul, Lambert, Kirsten, Li, Stephen C. H., Malan, Wynand, Maticevic, Stjepana, McQuillan, Brendan M., Mirzaee, Sam, Mori, Trevor A., Morton, Allison C., Colquhoun, David M., Moullin, Joanna C., Nestel, Paul J., Nowak, Kristen J., O'Brien, Richard C., Pachter, Nicholas, Page, Michael M., Pedrotti, Annette, Psaltis, Peter J., Radford, Jan, Reid, Nicola J., Robertson, Elizabeth N., Ryan, Jacqueline D. M., Sarkies, Mitchell N., Schultz, Carl J., Scott, Russell S., Semsarian, Christopher, Simons, Leon A., Spinks, Catherine, Tonkin, Andrew M., van Bockxmeer, Frank, Waddell-Smith, Kathryn E., Ward, Natalie C., White, Harvey D., Wilson, Andrew M., Winship, Ingrid, Woodward, Ann Marie, Nicholls, Stephen J., FH Australasia Network Consensus Working Group, <p>Raine Clinical Research Fellowship Western Australian Health Translation Network (WAHTN) Early Career Fellowship Australian Government's Medical Research Future Fund</p>, Watts, Gerald F., Sullivan, David R., Hare, David L., Kostner, Karam M., Horton, Ari E., Bell, Damon A., Brett, Tom, Trent, Ronald J., Poplawski, Nicola K., Martin, Andrew C., Srinivasan, Shubha, Justo, Robert N., Chow, Clara K., Pang, Jing, Ademi, Zanfina, Ardill, Justin J., Barnett, Wendy, Bates, Timothy R., Beilin, Lawrence J., Bishop, Warrick, Black, J. Andrew, Brett, Peter, Brown, Alex, Burnett, John R., Bursill, Christina A., Colley, Alison, Clifton, Peter M., Ekinci, Elif I., Elias, Luke, Figtree, Gemma A., Forge, Brett H., Garton-Smith, Jacquie, Graham, Dorothy F., Hamilton-Craig, Ian, Hamilton-Craig, Christian R., Heal, Clare, Hespe, Charlotte M., Hooper, Amanda J., Howes, Laurence G., Ingles, Jodie, Irvin, John, Janus, Edward D., Kangaharan, Nadarajah, Keech, Anthony C., Kirke, Andrew B., Kritharides, Leonard, Kyle, Campbell V., Lacaze, Paul, Lambert, Kirsten, Li, Stephen C. H., Malan, Wynand, Maticevic, Stjepana, McQuillan, Brendan M., Mirzaee, Sam, Mori, Trevor A., Morton, Allison C., Colquhoun, David M., Moullin, Joanna C., Nestel, Paul J., Nowak, Kristen J., O'Brien, Richard C., Pachter, Nicholas, Page, Michael M., Pedrotti, Annette, Psaltis, Peter J., Radford, Jan, Reid, Nicola J., Robertson, Elizabeth N., Ryan, Jacqueline D. M., Sarkies, Mitchell N., Schultz, Carl J., Scott, Russell S., Semsarian, Christopher, Simons, Leon A., Spinks, Catherine, Tonkin, Andrew M., van Bockxmeer, Frank, Waddell-Smith, Kathryn E., Ward, Natalie C., White, Harvey D., Wilson, Andrew M., Winship, Ingrid, Woodward, Ann Marie, Nicholls, Stephen J., and FH Australasia Network Consensus Working Group
- Abstract
Watts, G. F., Sullivan, D. R., Hare, D. L., Kostner, K. M., Horton, A. E., Bell, D. A., ... Nicholls, S. J. (2021). Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia. Heart, Lung and Circulation, 30(3), 324-349. https://doi.org/10.1016/j.hlc.2020.09.943
64. Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: An Australian perspective
- Author
-
<p>WAHTN Early Career Fellowship Australian Government's Medical Research Future Fund</p>, Watts, Gerald F., Sullivan, David R., Hare, David L., Kostner, Karam M., Horton, Ari E., Bell, Damon A., Brett, Tom, Trent, Ronald J., Poplawski, Nicola K., Martin, Andrew C., Srinivasan, Shubha, Justo, Robert N., Chow, Clara K., Pang, Jing, Ademi, Zanfina, Ardill, Justin J., Barnett, Wendy, Bates, Timothy R., Beilin, Lawrence J., Bishop, Warrick, Black, J. Andrew, Brown, Alex, Burnett, John R., Bursill, Christina A., Colley, Alison, Clifton, Peter M., Ekinci, Elif I., Figtree, Gemma A., Forge, Brett H., Garton-Smith, Jacquie, Graham, Dorothy F., Hamilton-Craig, Ian, Hamilton-Craig, Christian R., Heal, Clare, Hespe, Charlotte M., Hooper, Amanda J., Howes, Laurence G., Ingles, Jodie, Janus, Edward D., Kangaharan, Nadarajah, Keech, Anthony C., Kirke, Andrew B., Kritharides, Leonard, Kyle, Campbell V., Lacaze, Paul, Li, Stephen C. H., Maticevic, Stjepana, McQuillan, Brendan M., Mirzaee, Sam, Mori, Trevor A., Morton, Allison C., Colquhoun, David M., Moullin, Joanna C., Nestel, Paul J., Nowak, Kristen J., O'Brien, Richard C., Pachter, Nicholas, Page, Michael M., Psaltis, Peter J., Radford, Jan, Reid, Nicola J., Robertson, Elizabeth N., Ryan, Jacqueline D. M., Sarkies, Mitchell N., Schultz, Carl J., Scott, Russell S., Semsarian, Christopher, Simons, Leon A., Spinks, Catherine, Tonkin, Andrew M., van Bockxmeer, Frank, Waddell-Smith, Kathryn E., Ward, Natalie C., White, Harvey D., Wilson, Andrew M., Winship, Ingrid, Woodward, Ann Marie, Nicholls, Stephen J., Brett, Peter, Elias, Luke, Malan, Wynand, Irvin, John, Lambert, Kirsten, Pedrotti, Annette, FH Australasia Network Consensus Working Group, <p>WAHTN Early Career Fellowship Australian Government's Medical Research Future Fund</p>, Watts, Gerald F., Sullivan, David R., Hare, David L., Kostner, Karam M., Horton, Ari E., Bell, Damon A., Brett, Tom, Trent, Ronald J., Poplawski, Nicola K., Martin, Andrew C., Srinivasan, Shubha, Justo, Robert N., Chow, Clara K., Pang, Jing, Ademi, Zanfina, Ardill, Justin J., Barnett, Wendy, Bates, Timothy R., Beilin, Lawrence J., Bishop, Warrick, Black, J. Andrew, Brown, Alex, Burnett, John R., Bursill, Christina A., Colley, Alison, Clifton, Peter M., Ekinci, Elif I., Figtree, Gemma A., Forge, Brett H., Garton-Smith, Jacquie, Graham, Dorothy F., Hamilton-Craig, Ian, Hamilton-Craig, Christian R., Heal, Clare, Hespe, Charlotte M., Hooper, Amanda J., Howes, Laurence G., Ingles, Jodie, Janus, Edward D., Kangaharan, Nadarajah, Keech, Anthony C., Kirke, Andrew B., Kritharides, Leonard, Kyle, Campbell V., Lacaze, Paul, Li, Stephen C. H., Maticevic, Stjepana, McQuillan, Brendan M., Mirzaee, Sam, Mori, Trevor A., Morton, Allison C., Colquhoun, David M., Moullin, Joanna C., Nestel, Paul J., Nowak, Kristen J., O'Brien, Richard C., Pachter, Nicholas, Page, Michael M., Psaltis, Peter J., Radford, Jan, Reid, Nicola J., Robertson, Elizabeth N., Ryan, Jacqueline D. M., Sarkies, Mitchell N., Schultz, Carl J., Scott, Russell S., Semsarian, Christopher, Simons, Leon A., Spinks, Catherine, Tonkin, Andrew M., van Bockxmeer, Frank, Waddell-Smith, Kathryn E., Ward, Natalie C., White, Harvey D., Wilson, Andrew M., Winship, Ingrid, Woodward, Ann Marie, Nicholls, Stephen J., Brett, Peter, Elias, Luke, Malan, Wynand, Irvin, John, Lambert, Kirsten, Pedrotti, Annette, and FH Australasia Network Consensus Working Group
- Abstract
Watts, G. F., Sullivan, D. R., Hare, D. L., Kostner, K. M., Horton, A. E., Bell, D. A., ... Pedrotti, A. (2021). Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: An Australian perspective. American Journal of Preventive Cardiology, 6, article 100151. https://doi.org/10.1016/j.ajpc.2021.100151
65. Management and Outcomes of Prosthetic Valve Thrombosis. An Australian Case Series From the Northern Territory.
- Author
-
Milne, Owen, Barthwal, Rohit, Agahari, Ian, Ilton, Marcus, and Kangaharan, Nadarajah
- Abstract
Background: Prosthetic valve thrombosis (PVT) is an uncommon but serious cause of morbidity and mortality after cardiac valve implantation. The most common cause leading to PVT is inadequate anticoagulation. Royal Darwin Hospital is a major referral centre for the Top End of Australia and is unique in having a high burden of rheumatic heart disease (RHD) requiring valve surgery, issues with adherence with oral anticoagulants, and the absence of onsite cardiothoracic facility.Methods: We report clinical characteristics and outcomes of consecutive patients presenting with PVT to a single centre without on-site cardiothoracic surgery.Results: Thirty-two (32) episodes involving 21 patients were retrospectively identified between 2000 and 2017. Our cohort had an average age of 37 years. Nineteen (19) patients were of Aboriginal or Torres Strait Islander descent. All valves were mechanical, except for one bioprosthetic mitral valve, with average time from implantation to initial PVT 5.1 years. The majority of patients were in New York Heart Association (NYHA) class III and IV (6%, and 66%, respectively). Anti-coagulation was sub-therapeutic in 88% of presentations. Eleven (11) (34%) presentations were recurrent PVT involving eight patients. Twenty-six (26) (82%) episodes were treated with thrombolytic therapy which achieved complete success in 65% and partial success in 19%. Five (5) patients received a second dose of the lytic agent. Of the four patients not responding to thrombolytic therapy, two died and two were urgently transferred to a facility with on-site cardiothoracic surgery. Five (5) out of 32 episodes resulted in death (16%) with overall mortality 24% for the cohort over the entire time period. Thrombolytic therapy was associated with five major bleeding episodes (16%) including two fatal bleeds.Conclusions: Prosthetic valve thrombosis is a rare but life-threatening complication of prosthetic valves, with the vast majority of patients found to be inadequately anticoagulated. Despite differences in thrombolytic agents these were successful in the majority of patients. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
66. Prevalence and burden of coronary artery disease on computed tomography coronary angiography and its correlation with high-density lipoprotein in the Northern Territory, Australia.
- Author
-
Baumann AAW, Roberts-Thomson RL, Shah R, Reynolds GF, Marangou J, Tayeb H, Psaltis PJ, Brown A, Wong D, Kangaharan N, and Ilton M
- Abstract
Indigenous Australians are known to have a higher prevalence of coronary artery disease (CAD) than non-Indigenous counterparts. Atherogenic lipid profiles, characterised by low serum levels of high-density lipoprotein (HDL) and higher serum triglycerides, have been shown to be more prevalent in Indigenous Australians. The use of computed tomography coronary angiography (CTCA) for risk stratification and diagnosis of CAD has been validated in moderate risk populations, but limited data exists in specific high-risk populations such as Indigenous Australians. Through a retrospective study of patient records, we aimed to confirm if an atherogenic lipid profile occurred in Indigenous Australians undergoing CTCA in the Northern Territory of Australia and if so, whether this correlated with the prevalence or burden of CAD. We demonstrate that Indigenous Australians have similar prevalence (52.6% vs . 50.3%, P=0.80) and burden of CAD (Leaman score 6.03±4.66 vs . 6.96±4.82, P=0.44) on CTCA as non-Indigenous patients, but were 8 years younger (41.9±8.9 vs . 50.0±11.9 years, P<0.001) at the time of examination. We confirmed the presence of an atherogenic lipid profile in Indigenous patients and showed low serum-HDL was associated with very premature (patients aged 18-35 years) CAD in comparison to premature (patients aged 36-55 years) and mature-onset (patients aged 56 years and older) CAD (0.71±0.25 vs . 1.09±0.35 vs . 1.18±0.36 mmol/L, P=0.009). Future clinical guidelines should consider the role of CTCA in Indigenous Australians and whether younger patients may benefit. The causes of premature CAD, including atherogenic lipid profiles, require an ongoing focus in order to achieve equitable cardiovascular outcomes for Indigenous and non-Indigenous Australians., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://cdt.amegroups.com/article/view/10.21037/cdt-23-458/coif). P.J.P. serves as an unpaid editorial board member of Cardiovascular Diagnosis and Therapy from July 2022 to June 2024. D.W. serves as an unpaid editorial board member of Cardiovascular Diagnosis and Therapy from February 2023 to January 2025. P.J.P. reports that he received speaker honoraria ad hoc from AstraZeneca and Boehringer Ingelheim related to antiplatelet/anticoagulant management of coronary syndromes; received support from Eli Lilly and NovoNordisk; and served as unpaid president of Australian Atherosclerosis Society. The other authors have no conflicts of interest to declare., (2024 Cardiovascular Diagnosis and Therapy. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
67. Protocol and rationale of the Australian multicentre registry for serial cardiac computed tomography angiography (ARISTOCRAT): a prospective observational study of the natural history of pericoronary adipose tissue attenuation and radiomics.
- Author
-
Cheng K, Lin A, Psaltis PJ, Rajwani A, Baumann A, Brett N, Kangaharan N, Otton J, Nicholls SJ, Dey D, and Wong DTL
- Abstract
Background: Vascular inflammation plays a crucial role in the development of atherosclerosis and atherosclerotic plaque rupture resulting in acute coronary syndrome (ACS). Pericoronary adipose tissue (PCAT) attenuation quantified from routine coronary computed tomography angiography (CCTA) has emerged as a promising non-invasive imaging biomarker of coronary inflammation. However, a detailed understanding of the natural history of PCAT attenuation is required before it can be used as a surrogate endpoint in trials of novel therapies targeting coronary inflammation. This article aims to explore the natural history of PCAT attenuation and its association with changes in plaque characteristics., Methods: The Australian natuRal hISTOry of periCoronary adipose tissue attenuation, RAdiomics and plaque by computed Tomographic angiography (ARISTOCRAT) registry is a multi-centre observational registry enrolling patients undergoing clinically indicated serial CCTA in 9 centres across Australia. CCTA scan parameters will be matched across serial scans. Quantitative analysis of plaque and PCAT will be performed using semiautomated software., Discussion: The primary endpoint is to explore temporal changes in patient-level and lesion-level PCAT attenuation by CCTA and their associations with changes in plaque characteristics. Secondary endpoints include evaluating: (I) impact of statin therapy on PCAT attenuation and plaque characteristics; and (II) changes in PCAT attenuation and plaque characteristics in specific subgroups according to sex and risk factors. ARISTOCRAT will further our understanding of the natural history of PCAT attenuation and its association with changes in plaque characteristics., Trial Registration: This study has been prospectively registered with the Australia and New Zealand Clinical Trials Registry (ACTRN12621001018808)., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://cdt.amegroups.com/article/view/10.21037/cdt-23-392/coif). P.J.P. serves as an unpaid editorial board member of Cardiovascular Diagnosis and Therapy from July 2022 to June 2024. S.J.N. as an unpaid editorial board member of Cardiovascular Diagnosis and Therapy from September 2023 to August 2025. D.T.L.W. serves as an unpaid editorial board member of Cardiovascular Diagnosis and Therapy from February 2021 to January 2023. K.C. was supported by the National Health and Medical Research Council postgraduate scholarship (No. APP2002573), which covers a portion of the research-related expenses and stipend to help with living expenses, research-related travel costs and other expenses associated with research project. S.J.N. received consulting fees from Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi- Regeneron, Vaxxinity, CSL Sequiris, and Novo Nordisk; received grants from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Cyclarity, Eli Lilly, Esperion, Resverlogix, New Amsterdam Pharma, Novartis, InfraReDx and Sanofi-Regeneron. D.T.L.W. received honoraria for lectures from Eli-Lilly, Pfizer and Boehringer. The other authors have no conflicts of interest to declare., (2024 Cardiovascular Diagnosis and Therapy. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
68. Prosthetic valve endocarditis presenting as meningoencephalitis complicated by pseudo-aneurysms in a remote Aboriginal healthcare setting in Australia: a case report.
- Author
-
Watson AL, Rice G, Hieu Vo T, and Kangaharan N
- Abstract
Background: The Australian Aboriginal population has a high burden of cardiac conditions predisposing patients to infective endocarditis. Pseudo-aneurysms are a rare and potentially fatal complication of both prior valvular surgery and endocarditis., Case Summary: A 31-year-old female with a history of bicuspid aortic valve requiring valve replacement presented with meningoencephalitis. Transoesophageal echo and positive blood cultures for Staphylococcus aureus confirmed prosthetic valve endocarditis (PVE). Aortic root mycotic pseudo-aneurysms developed during antimicrobial therapy and two large pseudo-aneurysms remain post-redo valve, root and arch replacement., Discussion: Complications associated with PVE are common, especially due to S. aureus . Redo cardiac surgery is high risk, percutaneous treatments may be technically difficult due to altered post-operative anatomy, and medication adherence issues and lack of healthcare engagement further compromise optimal care in this patient population., (© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2021
- Full Text
- View/download PDF
69. Left atrial, pulmonary vein, and left atrial appendage anatomy in Indigenous individuals: Implications for atrial fibrillation.
- Author
-
Clarke NAR, Kangaharan N, Costello B, Tu SJ, Hanna-Rivero N, Le K, Agahari I, Choo WK, Pitman BM, Gallagher C, Haji K, Roberts-Thomson KC, Sanders P, and Wong CX
- Abstract
Background: Indigenous Australians experience a greater burden of AF. Whether this is in-part due to differences in arrhythmogenic structures that appear to contribute to AF differences amongst other ethnicities is not known., Methods: We studied forty individuals matched for ethnicity and other AF risk factors. Computed tomography imaging was used to characterise left atrial (LA), pulmonary vein (PV), and left atrial appendage (LAA) anatomy., Results: There were no significant differences in LA diameters or volumes between Indigenous and non-Indigenous Australians. Similarly, we could not detect any consistent differences in PV number, morphology, diameters, or ostial characteristics according to ethnicity. LAA analyses suggested that Indigenous Australians may have a greater proportion of non chickenwing LAA type, and a tendency for eccentric, oval-shaped LAA ostia; however, there were no other differences seen with regards to LAA volume or depth. Indexed values for LA, PV and LAA anatomy corrected for body size were broadly similar., Conclusions: In a cohort of individuals matched for AF risk factors, we could find no strong evidence of ethnic differences in LA, PV, and LAA characteristics that may explain a predisposition of Indigenous Australians for atrial arrhythmogenesis. These findings, in conjunction with our previous data showing highly prevalent cardiometabolic risk factors in Indigenous Australians with AF, suggest that it is these conditions that are more likely responsible for the AF substrate in these individuals. Continued efforts should therefore be directed towards risk factor management in an attempt to prevent and minimise the effects of AF in Indigenous Australians., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.